ArticleJournal of cardiothoracic surgery2026
A model for predicting the therapeutic efficacy of bronchial artery embolization in treating hemoptysis.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the prognostic factors of bronchial artery embolization (BAE) for hemoptysis. Please verify if the provided city are correct and amend if necessary." Resolved="yes"-->
methodsInitially, we collected information on 179 patients who underwent BAE for hemoptysis in the Department of Interventional Vascular Medicine of Jiangxi Provincial Chest Hospital and the Department of Respiratory and Critical Care Medicine of the First People's Hospital of Jingdezhen from March 2023 to August 2023. Further, the correlation between different influencing factors and the clinical success rate of the procedure was assessed. The most relevant prognostic factors were selected using the univariate analysis and LASSO, performing the logistic regression modeling for the final selected predictors.
resultsAmong the selected subjects (n = 160), the technical and clinical success rates of BAE were 99% (159/160) and 86.25% (138/160), respectively. The predictive factors associated with the reduced clinical success were hemoptysis due to lung tumors, severe hemoptysis, recent anticoagulant/antiplatelet drugs, the presence of pulmonary artery pseudoaneurysm, and elevated blood sedimentation values. The developed model from these five predictors showed excellent ability with a well-calibrated area under the curve (AUC) of 0.864.
conclusionIn summary, the developed model could feasibly predict the clinical success of BAE for hemoptysis, which could promptly support clinicians in making decisions on treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.